MedTrace Logo

Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting Conditions

NCT00865176 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-03-29

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the relative bioequivalence of Eplerenone 50 mg ER Tablets under fasting conditions.

Conditions

Interventions

DRUG

Eplerenone 50 mg Tablets Sandoz Inc., USA

DRUG

Inspra 50 mg Tablets GD Searle LLC, USA

Sponsors & Collaborators

Principal Investigators

  • Deepen Patel, M.D., CCFP · Allied Research International Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2006-07-31
Completion
2006-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00865176 on ClinicalTrials.gov